Nasal Eosinophilia and Serum Soluble Intercellular Adhesion Molecule 1 in Patients with Allergic Rhinitis Treated with Montelukast Alone or in Combination with Desloratadine or Levocetirizine

Ciebiada, Maciej; Barylski, Marcin; Górska-Ciebiada, Małgorzata

doi:10.2500/ajra.2013.27.3881

Cited by 17 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also in vivo studies that revealed the anti-inflammatory effect of H1 antihistamines. Both desloratadine and levocetirizine reduced ICAM-1 and nasal Eo [ 44 ], similar to present results. In the present study, VCAM-1 was not reduced by AH1, only ICAM-1 and E-selectin.…”

Section: Discussionsupporting

confidence: 91%

How Could We Influence Systemic Inflammation in Allergic Rhinitis? The Role of H1 Antihistamines

Muntean

Bocşan

Miron

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The aim of the study was the analysis of adhesion molecules' profile (ICAM-1, VCAM-1, and E-selectin) in patients with allergic rhinitis and the influence of H1 antihistamines on those markers. Seventy-nine patients with persistent allergic rhinitis (PAR) and 30 healthy volunteers were included in the study. The patients with PAR were treated with desloratadine 5 mg/day or levocetirizine 5 mg/day for 4 weeks. The clinical (rhinitis symptoms and total symptoms score (TSS), type of sensitization) and biological evaluation (total IgE, eosinophils, ICAM-1, VCAM-1, and E-selectin) as well as fractionate nitric oxide in exhaled air (FeNO) measurement was performed before and after treatment. The plasmatic levels of ICAM-1, VCAM-1, total IgE, and eosinophils and FeNO were significantly increased in patients with PAR compared to healthy volunteers. H1 antihistamines significantly improved TSS, with no differences between the investigated drugs. There was a significant decrease of eosinophils, total IgE, and FeNO after treatment. H1 antihistamines significantly decreased the plasmatic levels of ICAM-1 and E-selectin but not VCAM-1 compared to basal values. There is no difference between levocetirizine and desloratadine in the reduction of CAMs. A systemic inflammation characterized by increased levels of CAMs is present in patients with PAR. H1 antihistamines improve symptoms and reduce CAMs and FeNO levels after 1 month of treatment. H1 antihistamines might reduce the systemic inflammation which could be responsible to asthma occurrence in patients with PAR.

show abstract

Section: Discussionsupporting

confidence: 91%

How Could We Influence Systemic Inflammation in Allergic Rhinitis? The Role of H1 Antihistamines

Muntean

Bocşan

Miron

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Our study results, thus, support other earlier studies [6,7,17] which evaluated the anti-allergic effect of various antihistamines and their combination with montelukast in AR. In these [12,13] studies, along with subjective symptoms, objective evidence of anti-allergy such as domiciliary nasal peak flow, nasal eosinophilia, and serum soluble intracellular adhesion molecule were also measured, and individual antihistamines had upper hand over their combinations with montelukast.…”

Section: Discussionsupporting

confidence: 83%

“…To contradict this finding, many comparative studies in AR patients have concluded that individual antihistamines such as fexofenadine, loratadine, [12] and desloratidine [7,13] are as effective as their combinations with montelukast, thus not justifying the various fixed-dose combinations (FDC) of antihistamines with montelukast available in market. Literature survey also revealed that comparative studies of other antihistamines in AR such as ebastine, a secondgeneration drug, with its combination with montelukast are very much scanty.…”

Section: Introductionmentioning

confidence: 91%

“…They decrease the subjective nasal symptoms such as sneezing, itching, congestion, and discharge and also extranasal symptoms such as eye redness, itching, and lacrimation and meanwhile improves the QOL. There are also objective evidence of betterment of disease by improving nasal peak flow, [6] decrease in nasal eosinophils, reduced serum soluble intracellular adhesion molecule, [7] and experimentally induced nasal congestion. [8] Montelukast, an antileukotriene drug, is also used extensively in AR treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis

Rajashekar¹,

Shobha²

2017

Natl J Physiol Pharm Pharmacol

View full text Add to dashboard Cite

Background: Antiallergic drugs are widely prescribed in allergic rhinitis (AR). Antihistamines and antileukotrienes are effective only in providing symptomatic relief of allergic symptoms, often used as fixed dose combinations (FDC) of both. Controversial reports regarding their efficacy in AR, when used alone or in their combined preparations, prompted the present study. Aims and Objectives: The aim of this study was to compare the anti-allergic effect of ebastine, montelukast, and their FDC on the subjective nasal and extranasal symptoms in mild-to-moderate persistent AR (PAR) patients. Materials and Methods: Mild-to-moderate PAR patients divided into three groups to receive drugs ebastine, montelukast, and their combined preparation for 3 weeks. Their efficacy was measured by total five nasal symptoms scoring system, AM, and PM symptom scores. The treatment was withdrawn in the last week, to assess the persisting anti-allergic action of treatment drugs. Results: When compared to baseline values, all the treatment groups showed a significant decrease in the total mean score of allergic symptoms. Ebastine and its combination with montelukast significantly decreased both AM and PM mean scores, but montelukast did only for PM mean score. Among three compared groups, ebastine and its combined preparation with montelukast were found significant in reducing total and AM symptoms. Conclusion: All 3 groups showed anti-allergic effects in a variable manner. Montelukast controlled daytime symptoms better. Ebastine and its combination with montelukast controlled allergic symptoms to a similar extent.

show abstract

“…The contained ginsenosides can exert a controlled glucocorticoid-like effect. 29,30 Safety issues associated with long-term administration of KRG should be considered. A multicenter, double-blind, randomized, placebo-controlled trial, involving 100 patients and conducted over a 24-week period, revealed no significant differences in adverse events between KRG and placebo groups.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Korean Red Ginseng on Symptoms and Inflammation in Patients With Allergic Rhinitis

Jung

Kang

et al. 2020

Ear Nose Throat J

View full text Add to dashboard Cite

Korean red ginseng (KRG) has been traditionally used in Korea for health improvement. However, the clinical effect of KRG intake on the symptoms in patients with allergic rhinitis remains unknown. Our study was performed to identify the clinical effects of KRG on patients with allergic rhinitis and to examine the effect of KRG on allergic inflammatory reaction. We evaluated 60 patients with allergic rhinitis. All the patients were treated for 4 weeks. The patients were divided into 3 groups, according to the medication. Twenty patients were treated with KRG, 20 patients with the placebo, and 20 patients with the antihistamine. The patients recorded their symptoms in a daily symptom diary card. The patients checked the peak nasal inspiratory flow rate 2 times a day. Total serum immunoglobulin E (IgE) and serum-specific IgE were measured by ImmunoCap method before and after 4-week medication. The Th2 cytokines interleukin-4 (IL-4), IL-5, and IL-10 were checked in the serum before and after the 4-week treatment. The eosinophil counts in the nasal smears were checked. Korean red ginseng group has shown the significant improvement in rhinorrhea, nasal itching, and eye itching. Both the antihistamine and KRG groups showed a significant decrease in total IgE level at the end of treatment. The serum IL-4 level and eosinophil counts in the nasal smears were significantly decreased both in the antihistamine and in the KRG groups. In conclusion, KRG might be a useful treatment modality for patients with allergic rhinitis.

show abstract

Nasal Eosinophilia and Serum Soluble Intercellular Adhesion Molecule 1 in Patients with Allergic Rhinitis Treated with Montelukast Alone or in Combination with Desloratadine or Levocetirizine

Cited by 17 publications

References 36 publications

How Could We Influence Systemic Inflammation in Allergic Rhinitis? The Role of H1 Antihistamines

How Could We Influence Systemic Inflammation in Allergic Rhinitis? The Role of H1 Antihistamines

Randomized prospective double-blind comparative clinical study of ebastine and its combined preparation of montelukast in persistent allergic rhinitis

The Effect of Korean Red Ginseng on Symptoms and Inflammation in Patients With Allergic Rhinitis

Contact Info

Product

Resources

About